Special issue “The advance of solid tumor research in China”: Real‐world clinical outcomes of alectinib for advanced nonsmall‐cell lung cancer patients with ALK fusion in China
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Cancer"
DOI: 10.1002/ijc.34123
Abstract: Global phase 3 trials have demonstrated the priority of several next‐generation anaplastic lymphoma kinase‐tyrosine kinase inhibitors (ALK‐TKIs). However, clinical studies are conducted with specific populations that differ from the real world. The study aimed to… read more here.
Keywords: clinical outcomes; world; outcomes alectinib; china ... See more keywords
ALK detection in lung cancer: identification of atypical and cryptic ALK rearrangements using an optimal algorithm
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Cancer Research and Clinical Oncology"
DOI: 10.1007/s00432-020-03166-1
Abstract: Purpose IHC, FISH, and NGS are common methods of ALK evaluation in NSCLC. The purpose of this study was to investigate whether ALK false positives or false negatives occurred more often in daily routines. An… read more here.
Keywords: alk fusion; alk; alk ihc; cancer ... See more keywords
Variability in lung cancer response to ALK inhibitors cannot be explained by the diversity of ALK fusion variants.
Sign Up to like & getrecommendations! Published in 2018 at "Biochimie"
DOI: 10.1016/j.biochi.2018.07.018
Abstract: Multiple laboratory evidences indicate that distinct variants of ALK translocations differ in their biochemical properties and responsiveness to ALK tyrosine kinase inhibitors (TKIs). These data are supported by some clinical studies, which showed improved responses… read more here.
Keywords: alk inhibitors; alk fusion; alk; fusion variants ... See more keywords
PLEKHM2-ALK: A novel fusion in small-cell lung cancer and durable response to ALK inhibitors.
Sign Up to like & getrecommendations! Published in 2019 at "Lung cancer"
DOI: 10.1016/j.lungcan.2019.11.002
Abstract: OBJECTIVES In non-small cell lung cancer (NSCLC), anaplastic lymphoma kinase (ALK) rearrangement identifies a subgroup of patients who are sensitive to ALK tyrosine kinase inhibitors (TKIs). ALK fusion is extremely rare in small-cell lung cancer… read more here.
Keywords: alk inhibitors; alk fusion; alk; lung cancer ... See more keywords
Distribution of EML4-ALK fusion variants and clinical outcomes in patients with resected non-small cell lung cancer.
Sign Up to like & getrecommendations! Published in 2020 at "Lung cancer"
DOI: 10.1016/j.lungcan.2020.09.012
Abstract: OBJECTIVES The molecular profiles and prognosis of anaplastic lymphoma kinase (ALK) fusion and resectable non-small cell lung cancer (NSCLC) remain unclear. This study aimed to explore the distribution of ALK fusion variants and prognostic factors… read more here.
Keywords: alk fusion; alk; fusion variants; lung cancer ... See more keywords
Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers.
Sign Up to like & getrecommendations! Published in 2017 at "Pharmacological research"
DOI: 10.1016/j.phrs.2017.01.007
Abstract: Anaplastic lymphoma kinase is expressed in two-thirds of the anaplastic large-cell lymphomas as an NPM-ALK fusion protein. Physiological ALK is a receptor protein-tyrosine kinase within the insulin receptor superfamily of proteins that participates in nervous… read more here.
Keywords: alk fusion; alk; kinase; cell ... See more keywords
Epithelioid fibrous histiocytoma: molecular characterization of ALK fusion partners in 23 cases
Sign Up to like & getrecommendations! Published in 2018 at "Modern Pathology"
DOI: 10.1038/modpathol.2017.191
Abstract: Epithelioid fibrous histiocytoma is a rare and distinctive cutaneous neoplasm. Most cases harbor ALK rearrangement and show ALK overexpression, which distinguish this neoplasm from conventional cutaneous fibrous histiocytoma and variants. SQSTM1 and VCL have previously… read more here.
Keywords: alk fusion; alk; epithelioid fibrous; fibrous histiocytoma ... See more keywords
Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches
Sign Up to like & getrecommendations! Published in 2017 at "Scientific Reports"
DOI: 10.1038/s41598-017-12679-8
Abstract: Rearrangements of the anaplastic lymphoma kinase (ALK) gene in non-small cell lung cancer (NSCLC) represent a novel molecular target in a small subset of tumors. Although ALK rearrangements are usually assessed by immunohistochemistry (IHC) and… read more here.
Keywords: alk fusion; alk; lung cancer; next generation ... See more keywords
ALK fusion NSCLC oncogenes promote survival and inhibit NK cell responses via SERPINB4 expression
Sign Up to like & getrecommendations! Published in 2023 at "Proceedings of the National Academy of Sciences of the United States of America"
DOI: 10.1073/pnas.2216479120
Abstract: Significance In this work, we have developed a highly controlled non-tumorigenic human bronchial epithelial cell system expressing four ALK fusions found in NSCLC. Employing RNA-seq and phosphoproteomics, we identify both common and isoform-specific differentially expressed… read more here.
Keywords: cell; expression; alk; alk fusions ... See more keywords
Acquired EML4-ALK fusion and EGFR C797S in cis mutation as resistance mechanisms to osimertinib in a non-small cell lung cancer patient with EGFR L858R/T790M.
Sign Up to like & getrecommendations! Published in 2022 at "Anti-cancer drugs"
DOI: 10.1097/cad.0000000000001489
Abstract: The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) dramatically improve the clinical outcomes of non-small cell lung cancer (NSCLC) patients harboring EGFR-sensitive mutations. Despite the remarkable efficacy of first-and second-generation EGFR TKIs, disease… read more here.
Keywords: patient; resistance; mutation; egfr ... See more keywords
Response to treatment with an ALK-TKI in a patient with advanced lung adenocarcinoma with concurrent ALK fusion and high PD-L1 expression: A case report
Sign Up to like & getrecommendations! Published in 2022 at "Medicine"
DOI: 10.1097/md.0000000000030094
Abstract: Rationale: Previous studies have shown that PD-L1 TPS ≥50% in lung cancer rarely overlaps with driver oncogenes such as epidermal growth factor receptor and anaplastic lymphoma kinase (ALK). The initial gene detection of the patient… read more here.
Keywords: high expression; patient; alk; treatment ... See more keywords